+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Long-term evaluation of urinary copper excretion and non-caeruloplasmin associated copper in Wilson disease patients under medical treatment

Long-term evaluation of urinary copper excretion and non-caeruloplasmin associated copper in Wilson disease patients under medical treatment

Journal of Inherited Metabolic Disease 2019

Urinary copper excretion rates and non-caeruloplasmin associated copper concentrations are increased in patients with Wilson disease. However, there is little literature describing the monitoring of these parameters over the long term. This is a monocentric retrospective study including data collected between 2003 and 2015 from 321 patients with Wilson disease by chart review. The patients were under therapy with D-penicillamine, trientine, or zinc. 24-h urinary copper excretion rates, non-caeruloplasmin associated copper, and total serum copper concentrations were determined at the start of therapy, as well as 6, 12, 18, 24, 36, and ≥ 60 months after the start of therapy. For patients taking chelating agents, all parameters were measured while under continued therapy, as well as after a 48-h dose interruption. A mathematical formula to predict 24-h urinary copper excretion rates under different therapies was established. In all treatment groups, urinary copper excretion rates decreased over time, but the inter-individual variation of the results was high. Non-caeruloplasmin associated copper concentrations tended to decline over time, but with a higher variation of results than that observed for urinary copper excretion rates. Due to their variability, urinary copper excretion rates and serum copper concentrations are less than ideal parameters by which to monitor the benefit of a copper-reducing therapy. Urinary copper excretion rates seem to be more suitable than non-caeruloplasmin associated copper concentrations for this purpose.

(PDF emailed within 0-6 h: $19.90)

Accession: 066483034

Download citation: RISBibTeXText

PMID: 30746719

DOI: 10.1002/jimd.12046

Related references

Long-term evaluation of urinary copper excretion and non-caeruloplasmin associated copper in Wilson disease patients under medical treatment. Journal of Inherited Metabolic Disease 2018, 2018

The pattern of urinary copper excretion and its response to treatment in patients with Wilson's disease. Qjm 104(9): 775-778, 2012

Defective biliary copper excretion in Wilson's disease: The role of caeruloplasmin. European Journal of Clinical Investigation 26(10): 893-901, 1996

Urinary copper/zinc ratio: a promising parameter for replacement of 24-hour urinary copper excretion for diagnosis of Wilson's disease in children. World Journal of Pediatrics 6(2): 148-153, 2010

New insights into the pathogenesis of copper toxicosis in Wilson's disease: evidence for copper incorporation and defective canalicular transport of caeruloplasmin. Biochemical Journal 315: 851-855, 1996

The effect of long term treatment with penicillamine on the copper content in the liver in patients with Wilson's disease. Acta Hepato-Gastroenterologica 22(5): 292-296, 1975

Urinary copper excretion before and after oral intake of d-penicillamine in parents of patients with Wilson's disease. Digestive and Liver Disease 44(4): 323-327, 2012

Effects of long-term zinc treatment in Japanese patients with Wilson disease: efficacy, stability, and copper metabolism. Translational Research 156(6): 350-357, 2010

Appropriate administration schedule of D-penicillamine for pediatric Wilson's disease patients based on urinary copper excretion. Yakugaku Zasshi 122(8): 585-588, 2002

Studies with radioactive copper ( 64 Cu and 67 Cu); the incorporation of radioactive copper into caeruloplasmin in Wilson's disease and in primary biliary cirrhosis. Clinical Science 41(3): 189-202, 1971

Iatrogenic copper deficiency associated with long-term copper chelation for treatment of copper storage disease in a Bedlington Terrier. Journal of the American Veterinary Medical Association 218(10): 1593-7, 1580, 2001

Liver copper determination in long-term treatment of Wilson's disease with D-penicillamine. Die Medizinische Welt 32(3): 109-110, 1981

Is copper incorporation to caeruloplasmin normal in Wilson's disease?. Biochemical Society Transactions 22(2): 191s, 1994

Stimulated urinary copper excretion in the diagnosis of Wilson's disease. Gastroenterologia Y Hepatologia 38(7): 467, 2016

Checking of urinary copper in patients with Wilson's disease during treatment with D-penicillamine. Acta Neurologica. Quaderni 39: 160-164, 1979